Blue Cross was founded in 1980. It is one of the leading research-based pharmaceutical companies in India with over three decades of experience in providing healthcare products to people across the globe with the aim of improving human life.
It's name today is synonymous with top quality healthcare products. We discover, develop and deliver a wide range of innovative and highly advanced pharmaceutical products covering major therapeutic segments like Antibacterials, Pain Management, Antispasmodics, Cough & Cold Preparations, Cardiology, Diabetology, Dermatologicals, Anti-ulcerants, Antipyretics etc. in different dosage forms at Affordable cost.
It has state-of-the-art manufacturing plants at Nashik and Goa in India. These plants are modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical products.
幸运赛车It's plants are approved by F.D.A., W.H.O and many overseas countries for compliances with current G.M.P requirements. BLUE CROSS has been bestowed with several Quality Excellence Awards for both the manufacturing plants.
It's aim is to achieve world-class quality standards for all it's products。 To accomplish this Blue Crosss deploys rigorous testing and elaborate in-process control procedures backed by advanced quality assurance facilities。
It's unrelenting focus on research has helped to develop value added and novel drugs. It's R&D division is equipped with modern facilities. With the team consisting of dedicated and efficient research professionals with strong R&D capabilities, it conducts R & D on a broad range of therapeutic segments.
Blue Cross is now poised for a new phase of growth. To meet the challenges of the future, it has drawn up fresh strategies and planned new forays. It aims to strengthen it's presence further in therapeutic segments like Antibacterials, Anti-inflammatory, Analgesics, Nutritional, Cardiology and Diabetology by introducing new, improved molecules and dosage forms. It is also working towards introducing products in new therapeutic segments to broaden its base.